Skip to main content
Medical information Clinical review pending

Genetic Testing

RSPH1 Gene Primary Ciliary Dyskinesia Type 24 Genetic Test

Genetic test to identify mutations in the RSPH1 gene associated with Primary Ciliary Dyskinesia (PCD), a condition affecting cilia function and leading to respiratory and ENT issues.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No special preparation is required for a blood or saliva sample. Follow specific instructions provided by the laboratory if different.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RSPH1 Gene Primary Ciliary Dyskinesia Type 24 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Primary Ciliary Dyskinesia (PCD)
  • ✓Chronic respiratory infections (e.g., bronchitis, pneumonia)
  • ✓Chronic sinusitis
  • ✓Otitis media (middle ear infections)
  • ✓Hearing loss
  • ✓Infertility (in males)
  • ✓Family history of PCD
  • ✓Neonatal respiratory distress
02

In plain language

What this test helps you understand

This test helps identify individuals with mutations in the RSPH1 gene, confirming a diagnosis of PCD Type 24. Early diagnosis allows for appropriate management of respiratory and ENT symptoms, potentially reducing complications and improving quality of life. It also provides information for genetic counseling and family planning.
The RSPH1 Gene Primary Ciliary Dyskinesia Type 24 NGS Genetic DNA Test is a diagnostic tool used to identify specific genetic mutations in the RSPH1 gene. These mutations are linked to Primary Ciliary Dyskinesia (PCD), a rare genetic disorder affecting the function of cilia. Cilia are microscopic, hair-like structures found in various parts of the body, including the respiratory tract, that help move mucus and clear debris. Dysfunction of cilia can lead to chronic respiratory problems and ear, nose, and throat (ENT) disorders. Understanding your genetic status regarding PCD is important for diagnosis, management, and family planning. This test analyzes your DNA to detect variations in the RSPH1 gene.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for a blood or saliva sample. Follow specific instructions provided by the laboratory if different.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the RSPH1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the RSPH1 gene. PCD can be caused by mutations in other genes not covered by this test. A negative result does not completely rule out PCD. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

PCD is a rare genetic disorder affecting the cilia, tiny hair-like structures in the body. It can cause chronic respiratory infections, sinusitis, hearing loss, and other related issues.
Mutations in the RSPH1 gene are a known cause of PCD. Identifying these mutations helps confirm the diagnosis and understand the specific type of PCD.
Individuals with symptoms like chronic lung infections, persistent sinusitis, or hearing loss, especially if there's a family history of similar conditions, may benefit from this test.
Your doctor or a genetic counselor will help interpret the results and discuss their implications for your health, management, and family.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
A sample can be collected via a blood draw or a saliva sample. We offer convenient sample collection options, including home visits in major cities. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp